We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GET:EURONEXT PARISGetlink SE Analysis

Data as of 2026-06-23 - not real-time

$1.15

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading at $1.15, well below its 52‑week high of $3.21 and near the upper end of its 20‑day SMA of 0.86, indicating limited upside from a technical standpoint. The RSI of 66 suggests the shares are approaching overbought territory, while the MACD histogram has turned positive, offering a modest bullish signal. Volatility is extreme, with a 30‑day swing of over 218% and a beta of 1.76, underscoring the price’s sensitivity to market moves. Fundamental metrics show a forward P/E of 7.38 versus an industry average of 16.2, and a price‑to‑book below 1, pointing to a potentially undervalued valuation. However, the company posted a negative profit margin of -11% and a trailing EPS of -$0.26, reflecting ongoing earnings pressure. The balance sheet is heavily levered, with debt exceeding $1.98 bn and a debt‑to‑equity ratio above 300%, raising solvency concerns.
A pending merger under review by the UK CMA adds regulatory uncertainty, but could unlock synergies and improve cash generation if approved. The forward EPS of $0.156 and an upside/downside potential of roughly 240% suggest meaningful upside if the company can turn cash flow positive. The free cash flow remains deeply negative, and operating cash flow of $89 m is insufficient to cover debt service, highlighting liquidity strain. Despite these challenges, the price‑to‑sales multiple of 0.49 and a strong gross margin of 73% indicate a resilient core business. The market sentiment is in “Extreme Greed” territory (Fear‑Greed Index 85), which may be inflating short‑term buying pressure. Overall, investors must balance the attractive valuation against high volatility, debt load, and regulatory risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • High short‑term volatility and overbought RSI
  • Bearish trend direction despite a bullish MACD crossover
  • Pending CMA review of the merger adds uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued multiples relative to industry peers
  • Forward earnings upside and potential merger synergies
  • Strong gross margin and low price‑to‑sales ratio

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Long‑term demand for AI‑enhanced visual content
  • Value‑oriented valuation with forward P/E well below sector average
  • Potential debt restructuring post‑merger

Key Metrics & Analysis

Financial Health

Revenue Growth1.10%
Profit Margin-10.94%
P/E Ratio7.4
ROE-17.60%
ROA3.90%
Debt/Equity337.62
P/B Ratio0.9
Op. Cash Flow$89.8M
Free Cash Flow$-478697888
Industry P/E16.2

Technical Analysis

TrendBearish
RSI65.7
Support$0.58
Resistance$1.48
MA 20$0.86
MA 50$0.86
MA 200$1.29
MACDBullish
VolumeIncreasing
Fear & Greed Index85.43

Valuation

Target Price$3.93
Upside/Downside241.30%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.76
Volatility218.75%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.